<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cunningham, Muriel</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Laird, Peter W.</style></author><author><style face="normal" font="default" size="100%">Stearns, Vered</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Update on Epigenetic Agents in the Treatment of BC</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">30-31</style></pages><abstract><style  face="normal" font="default" size="100%">Different types of cancer have distinct DNA methylation profiles, and analyses of tumor samples have found that multiple genetic and epigenetic changes are associated with breast cancer. As some epigenetic changes may be reversible, administering epigenetic agents with other therapies may be potent combinations in the treatment of breast cancer.</style></abstract><number><style face="normal" font="default" size="100%">56</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>